Stock Track | Ligand Pharmaceuticals Soars 6.32% on Thursday Following Q4 Earnings Beat and Upbeat 2025 Guidance

Stock Track

Feb 27, 2025

Ligand Pharmaceuticals (NASDAQ:LGND) stock surged 6.32% in intraday trading on Thursday after reporting better-than-expected fourth quarter 2024 earnings and providing an optimistic outlook for 2025.

For the fourth quarter, Ligand posted adjusted earnings per share of $1.27, beating the consensus analyst estimate of $1.19. Total revenue of $42.81 million also exceeded expectations of $39.02 million. The strong quarterly results were driven by a 52.35% year-over-year increase in sales.

Looking ahead, Ligand forecasts full-year 2025 adjusted EPS of $6.00 to $6.25 on projected revenue between $180 million and $200 million. Analysts were expecting EPS of $6.07 on revenue of $187.1 million, so the company's guidance came in largely ahead of estimates.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1102065248"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1102065248\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1102065248?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 23:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102065248","market":"us","top_or_hot":-1,"title":"Stock Track | Ligand Pharmaceuticals Soars 6.32% on Thursday Following Q4 Earnings Beat and Upbeat 2025 Guidance","media":"Stock Track","content":"<p>Ligand Pharmaceuticals (NASDAQ:LGND) stock surged 6.32% in intraday trading on Thursday after reporting better-than-expected fourth quarter 2024 earnings and providing an optimistic outlook for 2025.</p>\n\n<p>For the fourth quarter, Ligand posted adjusted earnings per share of $1.27, beating the consensus analyst estimate of $1.19. Total revenue of $42.81 million also exceeded expectations of $39.02 million. The strong quarterly results were driven by a 52.35% year-over-year increase in sales.</p>\n\n<p>Looking ahead, Ligand forecasts full-year 2025 adjusted EPS of $6.00 to $6.25 on projected revenue between $180 million and $200 million. Analysts were expecting EPS of $6.07 on revenue of $187.1 million, so the company's guidance came in largely ahead of estimates.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ligand Pharmaceuticals Soars 6.32% on Thursday Following Q4 Earnings Beat and Upbeat 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ligand Pharmaceuticals Soars 6.32% on Thursday Following Q4 Earnings Beat and Upbeat 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 23:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ligand Pharmaceuticals (NASDAQ:LGND) stock surged 6.32% in intraday trading on Thursday after reporting better-than-expected fourth quarter 2024 earnings and providing an optimistic outlook for 2025.</p>\n\n<p>For the fourth quarter, Ligand posted adjusted earnings per share of $1.27, beating the consensus analyst estimate of $1.19. Total revenue of $42.81 million also exceeded expectations of $39.02 million. The strong quarterly results were driven by a 52.35% year-over-year increase in sales.</p>\n\n<p>Looking ahead, Ligand forecasts full-year 2025 adjusted EPS of $6.00 to $6.25 on projected revenue between $180 million and $200 million. Analysts were expecting EPS of $6.07 on revenue of $187.1 million, so the company's guidance came in largely ahead of estimates.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LGND","symbol_name":"Ligand Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1102065248","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102065248","pubTimestamp":1740670414,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ligand Pharmaceuticals  stock surged 6.32% in intraday trading on Thursday after reporting better-than-expected fourth quarter 2024 earnings and providing an optimistic outlook for 2025.For the fourth quarter, Ligand posted adjusted earnings per share of $1.27, beating the consensus analyst estimate of $1.19. Total revenue of $42.81 million also exceeded expectations of $39.02 million. The strong quarterly results were driven by a 52.35% year-over-year increase in sales.Looking ahead, Ligand for","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LGND":"Ligand Pharmaceuticals Inc."},"translate_title":"继第四季度盈利超出预期和乐观的2025年指引后，Ligand Pharmaceuticals周四飙升6.32%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":1},"content_text":"Ligand Pharmaceuticals (NASDAQ:LGND) stock surged 6.32% in intraday trading on Thursday after reporting better-than-expected fourth quarter 2024 earnings and providing an optimistic outlook for 2025.\nFor the fourth quarter, Ligand posted adjusted earnings per share of $1.27, beating the consensus analyst estimate of $1.19. Total revenue of $42.81 million also exceeded expectations of $39.02 million. The strong quarterly results were driven by a 52.35% year-over-year increase in sales.\nLooking ahead, Ligand forecasts full-year 2025 adjusted EPS of $6.00 to $6.25 on projected revenue between $180 million and $200 million. Analysts were expecting EPS of $6.07 on revenue of $187.1 million, so the company's guidance came in largely ahead of estimates.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}